International Journal of
Reproductive Biomedicine
Mon, Apr 7, 2025
[Archive]
Volume 19, Issue 5 (Suppl- 2021)
IJRM 2021, 19(5): 322-322 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zarbakhsh S, Safari R, Sameni HR, Yousefi B, Safari M, Khanmohammadi N et al . P-155 Impact of co-administration of bone marrow stromal cells and l-carnitine on rat damaged ovaries due to chemotherapy. IJRM 2021; 19 (5) :322-322
URL: http://ijrm.ir/article-1-2996-en.html
URL: http://ijrm.ir/article-1-2996-en.html
1- , szarbakhsh@yahoo.com
2- Department of Anatomy, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
3- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
2- Department of Anatomy, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
3- Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abstract: (288 Views)
Background: Despite the great benefits of chemotherapy in treating cancer patients, it has some side effects on ovaries. Cyclophosphamide is one of the most used chemotherapy drugs which directly damages ovaries. It has been observed that transplantation of bone marrow stromal cells (BMSCs), a type of mesenchymal stem cells, may treat ovarian damage after chemotherapy. On the other hand, L-carnitine (LC), as a flavonoid antioxidant, appears to play an essential role in fatty acid metabolism and has beneficial effects on damaged ovaries. In addition, LC has beneficial effects on differentiation and reduction of apoptosis in BMSCs.
Objective: The aim of this study was to investigate the effects of co-administration of BMSC + LC on ovarian function, structure and apoptosis after creating a chemotherapy model with cyclophosphamide in rat.
Materials and Methods: Forty female Wistar rats were intraperitoneally injected with cyclophosphamide for 14 days for chemotherapy-induced ovarian destruction. Then, the rats were randomly divided into four groups: I. control group, 25 μl of culture medium was directly injected into the bilateral ovaries, II. BMSC group, 2×106 BMSCs suspended in 25 μl of culture medium were directly injected into the bilateral ovaries, III. LC group, 200 mg/kg of LC was injected intraperitoneally one day before until seven days after chemotherapy, IV. Co-administration of BMSC + LC group, injection of BMSCs, and LC were performed together. Four weeks later, the function of the ovaries was evaluated by measuring the levels of serum estradiol (E2) and follicle-stimulating hormone using the enzyme-linked immunosorbent assay kit, the structure of the ovaries was evaluated by counting the number of ovarian follicles at different stages using hematoxylin and eosin staining, and apoptosis was investigated by evaluating the expression of ovarian B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) proteins using western blot were assessed.
Results: Co-administration of BMSC + LC was more effective in repairing damaged ovaries than the effect of their separate administration. Co-administration of BMSC + LC increased E2 and decreased follicle-stimulating hormone levels compared to the control group (p < 0.001). The number of follicles was higher in the co-administration of BMSC + LC group compared to the control group (p < 0.001). Co-administration of BMSC + LC increased Bcl-2 protein level, decreased Bax protein level and increased Bcl-2/Bax ratio (p < 0.001).
Conclusion: The effect of co-administration of BMSC + LC is probably more effective than the effect of their separate administration on the recovery of damaged ovaries by chemotherapy with cyclophosphamide in rat.
Objective: The aim of this study was to investigate the effects of co-administration of BMSC + LC on ovarian function, structure and apoptosis after creating a chemotherapy model with cyclophosphamide in rat.
Materials and Methods: Forty female Wistar rats were intraperitoneally injected with cyclophosphamide for 14 days for chemotherapy-induced ovarian destruction. Then, the rats were randomly divided into four groups: I. control group, 25 μl of culture medium was directly injected into the bilateral ovaries, II. BMSC group, 2×106 BMSCs suspended in 25 μl of culture medium were directly injected into the bilateral ovaries, III. LC group, 200 mg/kg of LC was injected intraperitoneally one day before until seven days after chemotherapy, IV. Co-administration of BMSC + LC group, injection of BMSCs, and LC were performed together. Four weeks later, the function of the ovaries was evaluated by measuring the levels of serum estradiol (E2) and follicle-stimulating hormone using the enzyme-linked immunosorbent assay kit, the structure of the ovaries was evaluated by counting the number of ovarian follicles at different stages using hematoxylin and eosin staining, and apoptosis was investigated by evaluating the expression of ovarian B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) proteins using western blot were assessed.
Results: Co-administration of BMSC + LC was more effective in repairing damaged ovaries than the effect of their separate administration. Co-administration of BMSC + LC increased E2 and decreased follicle-stimulating hormone levels compared to the control group (p < 0.001). The number of follicles was higher in the co-administration of BMSC + LC group compared to the control group (p < 0.001). Co-administration of BMSC + LC increased Bcl-2 protein level, decreased Bax protein level and increased Bcl-2/Bax ratio (p < 0.001).
Conclusion: The effect of co-administration of BMSC + LC is probably more effective than the effect of their separate administration on the recovery of damaged ovaries by chemotherapy with cyclophosphamide in rat.
Type of Study: Congress Abstract |
Subject:
Fertility & Infertility
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
